-
-
-
-
-
-
-
MAIA Biotechnology (MAIA) adds two oncologists to its SAB
-
-
-
-
-
-
-
MAIA Biotechnology (MAIA) CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders
-
-
-
-
-
-
-
MAIA Biotechnology (MAIA) Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
-
-
-
-
-
430,632 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

